Meperidine pharmacokinetics and effects on physiologic parameters and thermal threshold following intravenous administration of three doses to horses.
- Journal Article
Summary
This study investigates the effects of three different doses of meperidine, a synthetic opioid, on horses when administered intravenously. It reveals that while the drug can provide short-term pain relief, it can also produce adverse side effects, casting doubts on its routine use as a standalone treatment in equine medicine.
Research design and outcomes
The detailed explanation of the study is as follows:
- The investigation involved eight horses owned by a university. The subjects were divided evenly between males (geldings) and females (mares) aged between 3-8 years. The study used a randomized balanced 4-way cross-over design.
- The horses were given a single intravenous dose of either saline, or one of three doses of meperidine: 0.25 mg/kg, 0.5 mg/kg, or 1.0 mg/kg. Blood samples were collected before administration and at several stages up to 96 hours afterward.
- Plasma and urine samples were then evaluated to determine the levels of meperidine and its metabolite normeperidine, using a technique known as liquid chromatography-mass spectrometry.
- Various physiological measurements were monitored over the course of 6 hours post administration, including heart rate, step counts, packed cell volume, total plasma protein, and gastrointestinal sounds. The team also studied the impact of meperidine on thermal nociception (the animal’s reaction to potential harmful heat sources), calculating the thermal excursion observed in the process.
- The research found that meperidine was quickly metabolized into normeperidine. For the 0.5-1.0 mg/kg doses, the volume of distribution at steady state ranged from 0.829 ± 0.138-1.58 ± 0.280 L/kg, and systemic clearance from 18.0 ± 1.4-22.8 ± 3.60 mL/min/kg.
- Notable side effects were dose-dependent central nervous excitation, an increased heart rate, and skin reactions. The effects on thermal nociception were seen to be short-lived; up to 45 minutes at the 0.5 mg/kg dose and only up to 15 minutes at the 1.0 mg/kg dose.
Conclusion
The final results of this study do not endorse the general clinical use of intravenous meperidine at a dose of 1 mg/kg in horses. It suggests that while a 0.5 mg/kg dose could provide temporary pain relief, the accompanying erratic and/or short-term adverse effects imply that cautious consideration must be taken if it is to be used as the only agent at this dosage.
Cite This Article
Publication
Researcher Affiliations
- K.L. Maddy Equine Analytical Pharmacology Laboratory, School of Veterinary Medicine, University of California-Davis, CA, 95616, Davis, USA.
- Department of Veterinary Surgery and Radiology, School of Veterinary Medicine, University of California, Davis, USA.
- K.L. Maddy Equine Analytical Pharmacology Laboratory, School of Veterinary Medicine, University of California-Davis, CA, 95616, Davis, USA.
- Department of Population Health and Reproduction, School of Veterinary Medicine, University of California, Davis, USA.
- K.L. Maddy Equine Analytical Pharmacology Laboratory, School of Veterinary Medicine, University of California-Davis, CA, 95616, Davis, USA. hkknych@ucdavis.edu.
- Department of Veterinary Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, USA. hkknych@ucdavis.edu.
MeSH Terms
- Administration, Intravenous / veterinary
- Analgesics, Opioid / administration & dosage
- Analgesics, Opioid / adverse effects
- Analgesics, Opioid / pharmacokinetics
- Analgesics, Opioid / pharmacology
- Animals
- Central Nervous System / drug effects
- Female
- Heart Rate / drug effects
- Horses
- Hot Temperature
- Male
- Meperidine / administration & dosage
- Meperidine / adverse effects
- Meperidine / analogs & derivatives
- Meperidine / blood
- Meperidine / pharmacokinetics
- Meperidine / pharmacology
- Meperidine / urine
- Nociception / drug effects
- Urticaria
Conflict of Interest Statement
References
- Bennett RC, Steffey EP. Use of opioids for pain and anesthetic management in horses.. Vet Clin North Am Equine Pract 2002 Apr;18(1):47-60.
- NS M, GL C. Review of Equine Analgesics and Pain Management. AAEP Proc 2007;53:240–4.
- Baldo BA, Pham NH. Histamine-releasing and allergenic properties of opioid analgesic drugs: resolving the two.. Anaesth Intensive Care 2012 Mar;40(2):216-35.
- Latta KS, Ginsberg B, Barkin RL. Meperidine: a critical review.. Am J Ther 2002 Jan-Feb;9(1):53-68.
- Foreman JH, Ruemmler R. Efficacy of intramuscular meperidine hydrochloride versus placebo in experimental foot lameness in horses.. Equine Vet J Suppl 2013 Dec;(45):48-53.
- Muir WW, Robertson JT. Visceral analgesia: effects of xylazine, butorphanol, meperidine, and pentazocine in horses.. Am J Vet Res 1985 Oct;46(10):2081-4.
- Steffey E, Pascoe P. Isoflurane and opioid or alpha2-adrenergic drug interaction in horses. J Vet Anaesth 1994;21:43.
- DeRossi R, Sampaio BF, Varela JV, Junqueira AL. Perineal analgesia and hemodynamic effects of the epidural administration of meperidine or hyperbaric bupivacaine in conscious horses.. Can Vet J 2004 Jan;45(1):42-7.
- Skarda RT, Muir WW 3rd. Analgesic, hemodynamic, and respiratory effects induced by caudal epidural administration of meperidine hydrochloride in mares.. Am J Vet Res 2001 Jul;62(7):1001-7.
- Waterman AE, Amin A. The influence of surgery and anaesthesia on the pharmacokinetics of pethidine in the horse.. Equine Vet J Suppl 1992 Feb;(11):56-8.
- Alexander F, Collett RA. Pethidine in the horse.. Res Vet Sci 1974 Jul;17(1):136-7.
- Dahlström BE, Paalzow LK, Lindberg C, Bogentoft C. Pharmacokinetics and analgesic effect of pethidine (meperidine) and its metabolites in the rat.. Drug Metab Dispos 1979 Mar-Apr;7(2):108-12.
- Mather LE, Meffin PJ. Clinical pharmacokinetics of pethidine.. Clin Pharmacokinet 1978 Sep-Oct;3(5):352-68.
- Morrison JC, Douvas SG, Rhodes PG, Christie RJ, Bucovaz ET, Wiser WL. Meperidine and normeperidine metabolism in the rhesus monkey.. Int J Gynaecol Obstet 1984 Oct;22(5):345-8.
- Danziger LH, Martin SJ, Blum RA. Central nervous system toxicity associated with meperidine use in hepatic disease.. Pharmacotherapy 1994 Mar-Apr;14(2):235-8.
- Kaiko RF, Foley KM, Grabinski PY, Heidrich G, Rogers AG, Inturrisi CE, Reidenberg MM. Central nervous system excitatory effects of meperidine in cancer patients.. Ann Neurol 1983 Feb;13(2):180-5.
- Szeto HH, Inturrisi CE, Houde R, Saal S, Cheigh J, Reidenberg MM. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure of cancer.. Ann Intern Med 1977 Jun;86(6):738-41.
- Hamamoto-Hardman BD, Steffey EP, Weiner D, McKemie DS, Kass P, Knych HK. Pharmacokinetics and selected pharmacodynamics of morphine and its active metabolites in horses after intravenous administration of four doses.. J Vet Pharmacol Ther 2019 Jul;42(4):401-410.
- Reed R, Barletta M, Mitchell K, Hanafi A, Bullington A, Knych H, Quandt J, Ryan C, Giguère S. The pharmacokinetics and pharmacodynamics of intravenous hydromorphone in horses.. Vet Anaesth Analg 2019 May;46(3):395-404.
- Callaghan R, Desmond PV, Paull P, Mashford ML. Hepatic enzyme activity is the major factor determining elimination rate of high-clearance drugs in cirrhosis.. Hepatology 1993 Jul;18(1):54-60.
- Golder FJ, Wilson J, Larenza MP, Fink OT. Suspected acute meperidine toxicity in a dog.. Vet Anaesth Analg 2010 Sep;37(5):471-7.
- Moy KV, Ma JD, Best BM, Atayee RS. Factors impacting variability of the urinary normeperidine-to-meperidine metabolic ratio in patients with chronic pain.. J Anal Toxicol 2014 Jan-Feb;38(1):1-7.
- Duthie DJ, Nimmo WS. Adverse effects of opioid analgesic drugs.. Br J Anaesth 1987 Jan;59(1):61-77.
- Guedes AG, Papich MG, Rude EP, Rider MA. Comparison of plasma histamine levels after intravenous administration of hydromorphone and morphine in dogs.. J Vet Pharmacol Ther 2007 Dec;30(6):516-22.
- Hermens JM, Ebertz JM, Hanifin JM, Hirshman CA. Comparison of histamine release in human skin mast cells induced by morphine, fentanyl, and oxymorphone.. Anesthesiology 1985 Feb;62(2):124-9.
- Flacke JW, Flacke WE, Bloor BC, Van Etten AP, Kripke BJ. Histamine release by four narcotics: a double-blind study in humans.. Anesth Analg 1987 Aug;66(8):723-30.
- Poller C, Hopster K, Rohn K, Kästner SB. Evaluation of contact heat thermal threshold testing for standardized assessment of cutaneous nociception in horses - comparison of different locations and environmental conditions.. BMC Vet Res 2013 Jan 8;9:4.
- Poller C, Hopster K, Rohn K, Kästner SB. Nociceptive thermal threshold testing in horses - effect of neuroleptic sedation and neuroleptanalgesia at different stimulation sites.. BMC Vet Res 2013 Jul 9;9:135.
- Dönselmann Im Sande P, Hopster K, Kästner S. [Effects of morphine, butorphanol and levomethadone in different doses on thermal nociceptive thresholds in horses].. Tierarztl Prax Ausg G Grosstiere Nutztiere 2017 Apr 19;45(2):98-106.
- Elfenbein JR, Robertson SA, MacKay RJ, KuKanich B, Sanchez L. Systemic and anti-nociceptive effects of prolonged lidocaine, ketamine, and butorphanol infusions alone and in combination in healthy horses.. BMC Vet Res 2014;10 Suppl 1(Suppl 1):S6.
- Muir WW, Skarda RT, Sheehan WC. Cardiopulmonary effects of narcotic agonists and a partial agonist in horses.. Am J Vet Res 1978 Oct;39(10):1632-5.
- Söbbeler FJ, Kästner SB. Effects of transdermal lidocaine or lidocaine with prilocaine or tetracaine on mechanical superficial sensation and nociceptive thermal thresholds in horses.. Vet Anaesth Analg 2018 Mar;45(2):227-233.
Citations
This article has been cited 1 times.- Knych HK, Stucker K, Gretler SR, Kass PH, McKemie DS. Pharmacokinetics, adverse effects and effects on thermal nociception following administration of three doses of codeine to horses.. BMC Vet Res 2022 May 25;18(1):196.